Preview Mode Links will not work in preview mode

Jul 22, 2013

1) Rasmussen's encephalitis treated with natalizumab and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. John Mytinger interviews Prof. Heinz Wiendl about his paper on Rasmussen's encephalitis treated with natalizumab. Dr. Roy Strowd is reading our e-Pearl of the week about watching for Whipple's: Oculomasticatory myorhythmia. In the next part of the podcast Dr. Alberto Espay interviews Dr. Pooja Khatri on intra-arterial therapy being used as standard treatment for acute stroke. The participants had nothing to disclose except Prof. Wiendl, Drs. Strowd, Espay and Khatri.Prof. Wiendl received honoraria for travel to attend meetings from Bayer Schering Pharma, Biogen Idec, Elan Corporation, Sanofi- Aventis, Schering-Plough Corp., Merck Serono, Teva Pharmaceuticals Industries Ltd.; has served as a consultant or is currently a consultant for Merck Serono, Medac, Inc, Sanofi-aventis, Biogen Idec, Bayer Schering Pharma, Novartis, Teva Pharmaceuticals Industries Ltd., Novo Nordisk; receives research support from Bayer Schering Pharma, Biogen Idec, Elan Corporation, Sanofi-aventis, Merck Serono, Teva Pharmaceuticals Industries Ltd., Novartis, Medac, Inc, Genzyme and Novo Nordisk.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; is a consultant for Chelsea Therapeutics; serves on the scientific advisory boards for Solvay Pharmaceuticals, Inc., Abbott (now Abbie), Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Merz Pharmaceuticals, LLC, Solstice Neurosciences, and Eli Lilly and Company, USWorldMeds; serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders; serves on the speakers' bureaus of Novartis, UCB, TEVA Pharmaceutical Industries Ltd, American Academy of Neurology, Movement Disorder Society and receives royalties from Lippincott, Williams & Wilkins and Cambridge University Press.Dr. Khatri received funding for a trip from Genetech, Inc.; provided expert witnessing for stroke cases over last two years; receives research support from Penumbra, Inc and the NIH.